Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
Li K, Zhong W, Fan J, Wang S, Yu D, Xu T, Lyu J, Wu S, Qin T, Wu Z, Xu L, Wu K, Liu Z, Hu Z, Li F, Wang J, Wang Q, Min J, Zhang Z, Yu L, Ding S, Huang L, Zhao T, Huang J, Lin T.
Li K, et al. Among authors: huang l, huang j.
Nat Cancer. 2024 Oct;5(10):1465-1478. doi: 10.1038/s43018-024-00822-0. Epub 2024 Sep 10.
Nat Cancer. 2024.
PMID: 39256488
Clinical Trial.